Reaux A, Fournie-Zaluski M C, Llorens-Cortes C
Institut National de la Santé et de la Recherche Médicale, Unité 36, Collège de France, Chaire de Médecine Expérimentale, 11 place Marcelin Berthelot, 75231 Paris Cedex 05, France.
Trends Endocrinol Metab. 2001 May-Jun;12(4):157-62. doi: 10.1016/s1043-2760(01)00381-2.
Among the main bioactive peptides of the brain renin-angiotensin system, angiotensin (Ang) II and AngIII exhibit the same affinity for type 1 and type 2 AngII receptors. Both peptides, injected intracerebroventricularly, cause similar increases in vasopressin release and blood pressure. Because AngII is converted in vivo to AngIII, the identity of the true effector is unknown. This review summarizes new insights into the predominant role of brain AngIII in the control of vasopressin release and blood pressure and underlines the fact that brain aminopeptidase A, the enzyme forming central AngIII, could constitute a putative central therapeutic target for the treatment of hypertension.
在脑肾素-血管紧张素系统的主要生物活性肽中,血管紧张素(Ang)II和AngIII对1型和2型AngII受体表现出相同的亲和力。将这两种肽经脑室内注射后,会引起血管加压素释放和血压的相似升高。由于AngII在体内会转化为AngIII,因此真正的效应因子尚不明确。本综述总结了关于脑AngIII在控制血管加压素释放和血压方面的主要作用的新见解,并强调了这样一个事实,即形成中枢AngIII的酶——脑氨肽酶A,可能构成治疗高血压的一个假定的中枢治疗靶点。